In a notable departure from decades of federal drug policy, President Trump signed an executive order directing agencies to accelerate their review of Schedule I psychedelics — including ibogaine — for potential medical use in treating depression, PTSD, and opioid addiction. The move reflects a quiet but growing consensus across political lines that prohibition has itself become an obstacle to understanding, and that veterans and others in crisis deserve access to every credible avenue of healing. Yet the order arrives alongside unresolved questions about cardiac risk and scientific readiness,
The Atlanta Journal-Constitution
· Apr 18, 2026
· health
· 1 min de leitura
High
Apuração: Verificado
Trump accelerates psychedelic drug reviews, including risky ibogaine treatment
◉
Politics & Governance
14378 artigos relacionados
Trump quips protester's mom voting for him at South Carolina Graham ra…
Fox News · 100% correspondência
Trump rallies for Graham in South Carolina runoff, downplays foreign p…
CBS News · 99% correspondência
Federal Judge Blocks Trump Immigration Freeze Affecting 39 Countries
NewsBreak · 99% correspondência
Federal Judge Strikes Down Trump's Voter Citizenship Executive Order
Fox News · 99% correspondência
Supreme Court temporarily allows Trump to fire independent agency offi…
Washington Examiner · 99% correspondência
Cobertura Relacionada
Google News · Aug 22
Canada-U.S. Trade Talks Collapse as Washington Imposes New Tariffs
Trade negotiations between Canada and the U.S. have broken down, prompting Washington to impose new tariffs including a …
The New York Times · Aug 22 Canada-U.S. Trade Talks Collapse as Tariffs Set to Take EffectTrade talks between Canada and the U.S. have broken down, with Mark Carney suspending negotiations. Mutual tariffs are n…
The Guardian · Aug 22 NS&I boosts premium bond odds again, adding 308,000 prizes in SeptemberNational Savings and Investments has increased premium bond prize fund rates to 4.35% annually, the second hike in two m…
BBC News · Aug 22 Canada suspends trade talks, vows 'dollar for dollar' tariff retaliationCanada suspends trade negotiations with the US after last-minute disagreements, triggering new 50% US tariffs on C$28bn …
Viés e Enquadramento
⚖
Article uses alarmist framing ('risky,' 'serious safety risks') while presenting Trump's psychedelic drug initiative, with corrupted body text limiting full bias assessment.
Bias Direction
center-left
Confidence
MED
Risk-emphasizing framing that leads with safety concerns and uses cautionary language ('despite safety concerns,' 'serious safety risks') before explaining potential medical benefits, creating a negative frame around the policy.
risky ibogaine treatment
serious safety risks
despite having serious safety risks
banned under the federal government's most restrictive category
Detailed medical evidence supporting psychedelic treatments for PTSD and depression
Perspectives from researchers or medical professionals advocating for expanded access
Comparative safety data between ibogaine and existing pharmaceutical treatments
Voices of patients who claim to have benefited from psychedelic treatments
Explanation of why conservative lawmakers support this (beyond 'embraced')
Impacto Geopolítico
🌎
Trump's executive order to accelerate psychedelic drug reviews, including risky ibogaine, signals U.S. domestic policy shift with limited direct geopolitical implications but potential soft power effects on global drug policy frameworks.
Escalation Risk
low
Confidence
MED
United States
West Africa
Global drug policy community
Domestic U.S. policy realignment toward medical psychedelics may influence international drug control treaties and WHO scheduling discussions. Conservative-bipartisan support suggests potential shift in U.S. negotiating positions on controlled substances at UN forums. West African nations (ibogaine source regions) may see increased geopolitical interest from U.S. pharmaceutical/research entities.
Similar to 1970s-80s U.S. cannabis rescheduling debates that preceded international treaty renegotiations; reflects broader trend of wealthy nations redefining drug policy independent of UN Single Convention framework.
Lente Econômica
📈
Trump's executive order to accelerate psychedelic drug reviews, including risky ibogaine, signals potential market expansion in mental health treatments but introduces regulatory uncertainty and safety concerns.
Market Signal
mixed
Confidence
MED
Pharmaceutical and Biotech
Mental Health Services
Healthcare/Medical Research
Addiction Treatment Industry
Regulatory Affairs
Potential access to novel treatments for depression, PTSD, and opioid addiction, but consumers face elevated safety risks from expedited review processes and limited clinical data on ibogaine's serious adverse effects.
Likely FDA regulatory framework changes to accelerate psychedelic drug approvals; potential conflict between expedited review timelines and safety standards; possible bipartisan legislative support for psychedelic research funding; increased scrutiny from medical safety organizations.